{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:57:16Z","timestamp":1786118236365,"version":"build-2736575974"},"reference-count":100,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Antigen-specific T-cell immunotherapies are transforming the treatment landscape of hematologic malignancies. Neoantigen-specific therapies that exploit the ability of endogenous T-cell receptors (TCRs) to recognize tumor-derived peptides in an HLA-restricted context differ mechanistically from modalities employing chimeric antigen receptor T cells, which target surface antigens in an HLA-independent manner. In contrast to approaches targeting tumor-associated antigens, neoantigen-specific strategies offer more precise tumor selectivity and reduced off-target toxicity. Advances in immunogenomics, immunopeptidomics, and functional validation have accelerated the identification of both personalized and recurrent neoantigens, and high-resolution sequencing technologies have further facilitated the characterization of their cognate TCRs, which are currently being explored for developing TCR-engineered T-cell therapies. Early-phase clinical trials in hematologic malignancies demonstrate that neoantigen-specific strategies are safe and feasible across multiple hematologic cancers, with ongoing studies actively assessing the immunogenicity, clinical efficacy, and durability of these approaches. This review synthesizes recent preclinical and clinical advances in the discovery, validation, and therapeutic exploitation of neoantigen-specific strategies in blood cancers, highlighting translational insights for prioritizing immunogenic neoantigens. Emphasis is placed on identifying biological and technological barriers that limit the therapeutic efficacy of neoantigen-specific immunotherapies, with the goal of distilling actionable insights to guide their development in hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030711","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:03:11Z","timestamp":1776704591000},"page":"669-681","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing neoantigen-specific T cells for precision immunotherapy in hematologic malignancies"],"prefix":"10.1182","volume":"148","author":[{"given":"Anmol","family":"Kandel","sequence":"first","affiliation":[{"name":"Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soung-Chul","family":"Cha","sequence":"additional","affiliation":[{"name":"Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2026080611221655400_bib1","doi-asserted-by":"crossref","first-page":"200978","DOI":"10.1016\/j.omton.2025.200978","article-title":"Shared neoantigens for cancer immunotherapy","volume":"33","author":"Goloudina","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"2026080611221655400_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2026080611221655400_bib3","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1182\/bloodadvances.2022007792","article-title":"Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma","volume":"8","author":"Ramirez","year":"2024","journal-title":"Blood Adv"},{"key":"2026080611221655400_bib4","doi-asserted-by":"crossref","first-page":"217427","DOI":"10.1016\/j.canlet.2024.217427","article-title":"Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy","volume":"611","author":"Jin","year":"2024","journal-title":"Cancer Lett"},{"key":"2026080611221655400_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2021.02.023","article-title":"Gene fusion neoantigens: emerging targets for cancer immunotherapy","volume":"506","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"issue":"3","key":"2026080611221655400_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"2026080611221655400_bib7","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/s41375-022-01705-y","article-title":"Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies","volume":"36","author":"Saini","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2026080611221655400_bib8","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-15-2023","article-title":"Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells","volume":"22","author":"Nielsen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2026080611221655400_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.03.047","article-title":"Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias","volume":"188","author":"Kim","year":"2025","journal-title":"Cell"},{"issue":"498","key":"2026080611221655400_bib10","doi-asserted-by":"crossref","first-page":"eaat8549","DOI":"10.1126\/scitranslmed.aat8549","article-title":"Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses","volume":"11","author":"Zamora","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"2026080611221655400_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2026080611221655400_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived neoantigen-specific T-cell responses in multiple myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026080611221655400_bib13","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/j.jtct.2025.01.619","article-title":"Neoantigen expression and expansion of cytotoxic T cell clonotypes in multiple myeloma patients randomized to post-transplant treatment with a personalized cancer vaccine under the BM CTN 1401 multicenter trial [abstract]","volume":"31","author":"Cheloni","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2026080611221655400_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"key":"2026080611221655400_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","article-title":"Neoantigens in hematologic malignancies","volume":"11","author":"Biernacki","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2026080611221655400_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41577-023-00986-3","article-title":"Alternative RNA splicing generates shared clonal neoantigens across different types of cancer","volume":"24","author":"Brown","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"2026080611221655400_bib17","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.3390\/ijms22179159","article-title":"Neoantigen-specific T-cell immune responses: the paradigm of NPM1-mutated acute myeloid leukemia","volume":"22","author":"Forghieri","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026080611221655400_bib18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstr\u00f6m","year":"2016","journal-title":"Leukemia"},{"key":"2026080611221655400_bib19","unstructured":"A study of VAC85135, a neoantigen vaccine regimen, concurrently administered with ipilimumab for the treatment of myeloproliferative neoplasms. ClinicalTrials.gov identifier: NCT05444530. Accessed 13 October 2025. https:\/\/clinicaltrials.gov\/study\/NCT05444530."},{"issue":"1","key":"2026080611221655400_bib20","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1038\/s41467-024-50880-2","article-title":"Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial","volume":"15","author":"Szymura","year":"2024","journal-title":"Nat Commun"},{"key":"2026080611221655400_bib21","unstructured":"Vaccine therapy for multiple myeloma utilizing idiotype-pulsed allogeneic dendritic cells. ClinicalTrials.gov identifier: NCT00186316. Accessed 22 August 2025. https:\/\/clinicaltrials.gov\/study\/NCT00186316."},{"issue":"9","key":"2026080611221655400_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2020008493","article-title":"A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma","volume":"139","author":"Qazilbash","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026080611221655400_bib23","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","article-title":"PGV001, a multi-peptide personalized neoantigen vaccine platform: phase I study in patients with solid and hematologic malignancies in the adjuvant setting","volume":"15","author":"Saxena","year":"2025","journal-title":"Cancer Discov"},{"key":"2026080611221655400_bib24","unstructured":"Vaccine therapy in treating patients with multiple myeloma. ClinicalTrials.gov identifier: NCT00019097. Accessed 13 October 2025. https:\/\/clinicaltrials.gov\/study\/NCT00019097."},{"key":"2026080611221655400_bib25","unstructured":"A personalized neoantigen cancer vaccine in treatment na\u00efve, asymptomatic patients with IGHV unmutated CLL. ClinicalTrials.gov identifier: NCT03219450. Accessed 13 October 2025. https:\/\/clinicaltrials.gov\/search?cond=NCT03219450."},{"key":"2026080611221655400_bib26","unstructured":"XP-005 personalized vaccine alone or in combination with toripalimab for the prevention of relapse after remission in acute myeloid leukemia. ClinicalTrials.gov identifier: NCT06980155. Accessed 13 October 2025. https:\/\/clinicaltrials.gov\/study\/NCT06980155."},{"issue":"10","key":"2026080611221655400_bib27","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-025-02710-7","article-title":"Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias: immunotherapy","volume":"39","author":"Tirtakusuma","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"2026080611221655400_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2141.2004.04873.x","article-title":"T cell recognition of BCR\/ABL in healthy donors and in patients with chronic myeloid leukaemia","volume":"125","author":"Westermann","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"2026080611221655400_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2026080611221655400_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41408-025-01370-1","article-title":"Identification of specific T-cell response and T-cell receptor targeting shared neoantigen for acute myeloid leukemia","volume":"15","author":"Zhou","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026080611221655400_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-018-0386-y","article-title":"Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies","volume":"6(1)","author":"Tubb","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2026080611221655400_bib32","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.3390\/curroncol30050348","article-title":"Identification and targeting of mutant neoantigens in multiple myeloma treatment","volume":"30","author":"Brancati","year":"2023","journal-title":"Curr Oncol"},{"issue":"9","key":"2026080611221655400_bib33","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/2326-6066.CIR-24-0091","article-title":"SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms","volume":"13","author":"Biernacki","year":"2025","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2026080611221655400_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/vaccines13020114","article-title":"Therapeutic vaccines for hematological cancers: a scoping review of this immunotherapeutic approach as alternative to the treatment of these malignancies","volume":"13","author":"Mathias","year":"2025","journal-title":"Vaccines"},{"issue":"8","key":"2026080611221655400_bib35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2026080611221655400_bib38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2026080611221655400_bib36","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026080611221655400_bib37","doi-asserted-by":"crossref","first-page":"e1219825","DOI":"10.1080\/2162402X.2016.1219825","article-title":"HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy","volume":"6","author":"Nelde","year":"2017","journal-title":"Oncoimmunology"},{"issue":"9","key":"2026080611221655400_bib39","first-page":"2268","article-title":"Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target","volume":"36","author":"Stevenson","year":"1977","journal-title":"Fed Proc"},{"issue":"7647","key":"2026080611221655400_bib40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"18","key":"2026080611221655400_bib41","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026080611221655400_bib42","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2026080611221655400_bib47","first-page":"e143072","article-title":"A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies [abstract]","volume":"37","author":"Blazquez","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080611221655400_bib44","unstructured":"Dendritic cells (DC)-based Id vaccination in stage-I myeloma. ClinicalTrials.gov identifier: NCT00988312. Accessed 22 August 2025. https:\/\/clinicaltrials.gov\/study\/NCT00988312."},{"issue":"10","key":"2026080611221655400_bib43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte\u2013monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"key":"2026080611221655400_bib45","unstructured":"Vaccine therapy in treating patients with multiple myeloma who have undergone stem cell transplantation. ClinicalTrials.gov identifier: NCT00002787. Accessed 13 October 2025. https:\/\/clinicaltrials.gov\/study\/NCT00002787."},{"key":"2026080611221655400_bib46","unstructured":"Autologous T cells transduced with retroviral vectors expressing TCRs for participant-specific neoantigens in patients with hematologic malignancies. ClinicalTrials.gov identifier: NCT06904066. Accessed 22 August 2025. https:\/\/clinicaltrials.gov\/study\/NCT06904066."},{"issue":"2","key":"2026080611221655400_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/bmt.2012.132","article-title":"Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients","volume":"48","author":"Foglietta","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2026080611221655400_bib49","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1182\/blood-2023-172688","article-title":"Kinetics of neoantigen specific T cells in post-transplant relapse [abstract]","volume":"142","author":"Neupane","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026080611221655400_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/cancers13020284","article-title":"Hematopoietic versus solid cancers and T cell dysfunction: looking for similarities and distinctions","volume":"13","author":"Montironi","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"2026080611221655400_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"24","key":"2026080611221655400_bib52","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026080611221655400_bib53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"issue":"14","key":"2026080611221655400_bib54","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2026080611221655400_bib55","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"2026080611221655400_bib56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","article-title":"Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression","volume":"3","author":"Han","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2026080611221655400_bib57","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V98.4.1070","article-title":"Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression","volume":"98","author":"Sotomayor","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2026080611221655400_bib58","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0301-472X(99)00083-1","article-title":"Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells","volume":"27","author":"Yotnda","year":"1999","journal-title":"Exp Hematol"},{"issue":"23","key":"2026080611221655400_bib59","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy","volume":"18","author":"Riches","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"8056","key":"2026080611221655400_bib60","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"issue":"24","key":"2026080611221655400_bib61","doi-asserted-by":"crossref","first-page":"21651","DOI":"10.1002\/cam4.6721","article-title":"The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"issue":"631","key":"2026080611221655400_bib62","doi-asserted-by":"crossref","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","article-title":"Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency","volume":"14","author":"Lahman","year":"2022","journal-title":"Sci Transl Med"},{"issue":"5","key":"2026080611221655400_bib63","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2010-06-292342","article-title":"Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma","volume":"117","author":"Navarrete","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2026080611221655400_bib64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2024.10.005","article-title":"Clonal hematopoiesis of indeterminate potential: the root cause of, and fertile ground for, hematological malignancies","volume":"31","author":"Zhuang","year":"2025","journal-title":"Trends Mol Med"},{"key":"2026080611221655400_bib65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/ITT.S534784","article-title":"T cells dysfunction in multiple myeloma","volume":"14","author":"Cai","year":"2025","journal-title":"ImmunoTargets Ther"},{"issue":"5","key":"2026080611221655400_bib66","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3324\/haematol.2020.267914","article-title":"T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","volume":"106","author":"Peters","year":"2021","journal-title":"Haematologica"},{"issue":"21","key":"2026080611221655400_bib67","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"2026080611221655400_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-019-0084-9","article-title":"RNA sequencing identifies clonal structure of T-cell repertoires in patients with adult T-cell leukemia\/lymphoma","volume":"4","author":"Farmanbar","year":"2019","journal-title":"NPJ Genom Med"},{"issue":"8","key":"2026080611221655400_bib69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026080611221655400_bib70","doi-asserted-by":"crossref","first-page":"2033433","DOI":"10.1080\/2162402X.2022.2033433","article-title":"CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: characterizing CD4+ T cells in Hodgkin lymphoma","volume":"11","author":"Veldman","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026080611221655400_bib71","doi-asserted-by":"crossref","first-page":"111927","DOI":"10.1016\/j.intimp.2024.111927","article-title":"Single-cell sequencing unveils T-cell characteristic in acute myeloid leukemia","volume":"132","author":"Zhu","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"2026080611221655400_bib72","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2026080611221655400_bib73","doi-asserted-by":"crossref","first-page":"e2101447","DOI":"10.1002\/advs.202101447","article-title":"Single-cell RNA-seq of T Cells in B-ALL patients reveals an exhausted subset with remarkable heterogeneity","volume":"8","author":"Wang","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2026080611221655400_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12943-022-01516-w","article-title":"BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion","volume":"21","author":"Liu","year":"2022","journal-title":"Mol Cancer"},{"issue":"6","key":"2026080611221655400_bib75","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.16260","article-title":"Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL","volume":"188","author":"Elston","year":"2020","journal-title":"Br J Haematol"},{"issue":"19","key":"2026080611221655400_bib76","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","article-title":"TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026080611221655400_bib77","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41375-023-02093-7","article-title":"Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution","volume":"38","author":"Suma","year":"2024","journal-title":"Leukemia"},{"key":"2026080611221655400_bib78","doi-asserted-by":"crossref","first-page":"107588","DOI":"10.1016\/j.leukres.2024.107588","article-title":"Gene regulatory mechanisms of T cell exhaustion in diffuse large B cell lymphoma based on single-cell transcriptome data","volume":"146","author":"Zhou","year":"2024","journal-title":"Leuk Res"},{"issue":"1","key":"2026080611221655400_bib79","first-page":"198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed Res Int"},{"issue":"1","key":"2026080611221655400_bib80","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12967-022-03798-6","article-title":"Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenstr\u00f6m macroglobulinemia","volume":"20","author":"Sun","year":"2022","journal-title":"J Transl Med"},{"issue":"5","key":"2026080611221655400_bib81","doi-asserted-by":"crossref","first-page":"e70055","DOI":"10.1111\/acel.70055","article-title":"Harnessing immune rejuvenation: advances in overcoming T cell senescence and exhaustion in cancer immunotherapy","volume":"24","author":"Admasu","year":"2025","journal-title":"Aging Cell"},{"issue":"1","key":"2026080611221655400_bib82","first-page":"1","article-title":"Immune microenvironment in hematologic malignancies","volume":"48","author":"Arandi","year":"2023","journal-title":"Iran J Med Sci"},{"key":"2026080611221655400_bib83","doi-asserted-by":"crossref","first-page":"943354","DOI":"10.3389\/fimmu.2022.943354","article-title":"Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies","volume":"13","author":"Maharaj","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2026080611221655400_bib84","first-page":"1832968","article-title":"Regulatory T cells and their prognostic relevance in hematologic malignancies","volume":"2017","author":"D\u2019Arena","year":"2017","journal-title":"J Immunol Res"},{"key":"2026080611221655400_bib85","doi-asserted-by":"crossref","first-page":"1016059","DOI":"10.3389\/fimmu.2022.1016059","article-title":"The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers","volume":"13","author":"Fan","year":"2022","journal-title":"Front Immunol"},{"issue":"20","key":"2026080611221655400_bib86","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.3390\/jcm10204665","article-title":"Hodgkin Lymphoma: a special microenvironment","volume":"10","author":"Opinto","year":"2021","journal-title":"J Clin Med"},{"issue":"21","key":"2026080611221655400_bib87","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1182\/blood.2020009855","article-title":"Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma","volume":"137","author":"Haebe","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026080611221655400_bib88","doi-asserted-by":"crossref","first-page":"110713","DOI":"10.1016\/j.celrep.2022.110713","article-title":"A single-cell atlas of diffuse large B cell lymphoma","volume":"39","author":"Ye","year":"2022","journal-title":"Cell Rep"},{"issue":"12","key":"2026080611221655400_bib89","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/cancers17121953","article-title":"Neoantigen-based immunotherapy in lung cancer: advances, challenges and prospects","volume":"17","author":"Li","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"2026080611221655400_bib90","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2026080611221655400_bib91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012414-040312","article-title":"Driver and passenger mutations in cancer","volume":"10","author":"Pon","year":"2015","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2026080611221655400_bib92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-025-01272-2","article-title":"Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1\/CD138\/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide","volume":"15","author":"Cirstea","year":"2025","journal-title":"Blood Cancer J"},{"issue":"17","key":"2026080611221655400_bib93","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/0008-5472.CAN-22-0917","article-title":"Metabolic reprogramming in hematologic malignancies: advances and clinical perspectives","volume":"82","author":"Yu","year":"2022","journal-title":"Cancer Res"},{"issue":"6","key":"2026080611221655400_bib94","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00262-006-0236-5","article-title":"T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005","volume":"56","author":"Ersvaer","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2026080611221655400_bib95","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"issue":"suppl 1","key":"2026080611221655400_bib96","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional hyper-expanded clonotypes and lack of TCR clonal replacement predict resistance to T cell engagers in multiple myeloma [abstract]","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026080611221655400_bib97","first-page":"684","article-title":"T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin lymphoma","volume":"39","author":"Klapper","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026080611221655400_bib98","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2026080611221655400_bib99","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"Van der Lee","year":"2019","journal-title":"J Clin Invest"},{"key":"2026080611221655400_bib100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.omtm.2023.05.014","article-title":"Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering","volume":"29","author":"Okada","year":"2023","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/669\/2536569\/blood_bld-2025-030711-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/669\/2536569\/blood_bld-2025-030711-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:22:39Z","timestamp":1786029759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/6\/669\/567846\/Harnessing-neoantigen-specific-T-cells-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030711","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,6]]},"published":{"date-parts":[[2026,8,6]]}}}